Plain-English translation of NCT06434064 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing whether combining (a hormone therapy pill) with pegylated liposomal doxorubicin (a chemotherapy drug given by IV infusion) can help treat advanced triple-negative breast cancer. The trial includes about 30 patients and is looking at how well this combination works, how safe it is, and how long people benefit from the treatment.
Triple-negative breast cancer is particularly challenging because standard hormone therapies don't work for it. This trial is exploring whether this medication combination might offer a new treatment option for people whose cancer has already been treated with other therapies.
You likely qualify if…
You likely don't qualify if…
You would take a daily pill at home and receive an IV infusion on the first day of each 28-day cycle. Throughout the study, you would have regular blood tests, heart imaging (echocardiogram), CT or MRI scans to monitor your tumor, and possibly a tumor biopsy. The study continues until your cancer progresses or you experience unacceptable side effects. After treatment ends, you would have a follow-up visit at 30 days and then every 6 months to monitor your health.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States